RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/15126570http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/15126570http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/15126570http://www.w3.org/2000/01/rdf-schema#comment"Congenital adrenal hyperplasia (CAH) is most commonly due to 21-hydroxylase deficiency and presents a wide spectrum of clinical manifestations from a severe classical form to a milder late-onset form with a variable severity of hyperandrogenic symptoms. A limited number of mutations account for the majority of the mutated alleles, but additional rare mutations are responsible for the symptoms in some patients. By CYP21 gene analysis, we identified a chimeric CYP21P/CYP21 gene with the fusion breakpoint downstream of the common P30L mutation as well as a GCC to ACC change at codon 15 (A15T) in two subjects with classical CAH and a CCC to TCC change at codon 482 (P482S) in seven subjects referred for nonclassical CAH, precocious pubarche, menstrual irregularities, or hypertrichosis. The two amino acid substitutions were reconstructed by in vitro site-directed mutagenesis, the proteins were transiently expressed in COS-1 cells, and enzyme activity toward the two natural substrates (17-hydroxyprogesterone and progesterone) was determined. The A15T mutant exhibited no significant difference in activity compared with the wild-type protein, whereas the P482S mutation reduced enzyme activity to 70% of normal. This impairment of activity was confirmed in vivo by detection of heterozygote carriers by the ACTH test."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.org/dc/terms/identifier"doi:10.1210/jc.2003-031630"xsd:string
http://purl.uniprot.org/citations/15126570http://purl.org/dc/terms/identifier"doi:10.1210/jc.2003-031630"xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Wedell A."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Wedell A."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Baldazzi L."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Baldazzi L."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Balsamo A."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Balsamo A."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Cacciari E."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Cacciari E."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Pirazzoli P."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Pirazzoli P."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Barbaro M."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Barbaro M."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Cicognani A."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Cicognani A."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Lajic S."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/author"Lajic S."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/date"2004"xsd:gYear
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/date"2004"xsd:gYear
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/name"J. Clin. Endocrinol. Metab."xsd:string
http://purl.uniprot.org/citations/15126570http://purl.uniprot.org/core/name"J. Clin. Endocrinol. Metab."xsd:string